Cumberland pharmaceuticals shares phase 2 fight dmd trial results at the parent project muscular dystrophy annual conference

New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in dmd patients nashville, tenn. , june 23, 2025 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company committed to developing new products for rare diseases, shared the latest positive results from its phase 2 fight dmd trial evaluating ifetroban, a novel oral therapy for duchenne muscular dystrophy (dmd) heart disease, at the annual parent project muscular dystrophy (ppmd) conference in las vegas.
CPIX Ratings Summary
CPIX Quant Ranking